$RGNX News

Last published 1w ago

1w agoRGNXREGENXBIO Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2w agoRGNXREGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational HighlightsPR NewswireROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m. ET to discuss its financial results for the third
1mo agoRGNXREGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20PR NewswireEvent to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc.
1mo agoRGNXREGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene...
2mo agoRGNXREGENXBIO to Participate in Upcoming Investor ConferencesPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference...
2mo agoRGNXREGENXBIO Strengthens Board of Directors with Appointment of Greg CiongoliPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple...
2mo agoRGNXREGENXBIO Announces Regulatory Update on RGX-121 for MPS IIPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of...
3mo agoRGNXREGENXBIO Reports Second Quarter 2026 Financial Results and Operational HighlightsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2026. "Our second...
3mo agoRGNXREGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational HighlightsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial...
3mo agoRGNXKuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX)...
3mo agoRGNXREGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual MeetingPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec,...
3mo agoRGNXREGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded WarrantsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of ...
4mo agoRGNXREGENXBIO Announces Proposed Public Offering of Common StockPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an ...
4mo agoRGNXKuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law FirmGlobeNewswireNEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ:RGNX) breached their fiduciary duties
4mo agoRGNXREGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million MilestonePR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational...
4mo agoRGNXREGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026PR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class...
4mo agoRGNXREGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS IIPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced it has aligned with the U.S. Food and Drug Administration (FDA) regarding the next steps needed for a...
5mo agoRGNXREGENXBIO to Participate in Upcoming Investor ConferencesPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare...
6mo agoRGNXREGENXBIO Reports First Quarter 2026 Financial Results and Operational HighlightsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the first quarter ended March 31, 2026. "REGENXBIO...
6mo agoRGNXREGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202PR NewswireREGENXBIO Inc. (Nasdaq: RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III...
6mo agoRGNXREGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual MeetingPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking...
6mo agoRGNXREGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular DystrophyPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast on Thursday, May 14, 2026, at 8:00 a.m. ET to discuss topline results from...
7mo agoRGNXSUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUDPR NewswireInstitutional investors holding positions in REGENXBIO, Inc. (NASDAQ: RGNX) during the period between February 9, 2022 and January 27, 2026 may wish...
8mo agoRGNXREGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202PR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential...
8mo agoRGNXREGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before April 14, 2026 to Discuss Your Rights – RGNXGlobeNewswireNEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ:RGNX). Shareholders who purchased shares of RGNX during the class period listed are
8mo agoWVE DNLI MRNA GMTX+6FDA reversals leave investors worrying about the fates of other experimental drugsCNBCInvestors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
8mo agoRGNXRGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLSTPR Newswire"Very promising results." That is how REGENXBIO, Inc. (NASDAQ: RGNX) characterized its RGX-111 gene therapy candidate as recently as January 2025. By ...
8mo agoRGNXREGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025....
8mo agoRGNXREGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferencePR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its RGX-202 investigational gene therapy for Duchenne muscular dystrophy at the 2026...
8mo agoRGNXREGENXBIO to Participate in Upcoming Investor ConferencesPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Leerink Partners Global Healthcare...
8mo agoRGNXREGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial...
8mo agoRGNXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNXPR NewswireThe Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the ...
9mo agoRGNXREGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS IIPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding...
9mo agoRGNXREGENXBIO Announces Regulatory Update on Ultra Rare MPS ProgramsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene...
10mo agoRGNXREGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy ProgramPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal ...
11mo agoRGNXREGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference. Presentation Details Date and...
11mo agoRGNXREGENXBIO to Participate in Upcoming Investor ConferencePR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference: Piper Sandler 37th Annual Healthcare...
1y agoRGNXREGENXBIO Reports Third Quarter 2025 Financial Results and Operational HighlightsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 2025. "The...
1y agoRGNXREGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy ProgramPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the AFFINITY DUCHENNE® pivotal trial of RGX-202, an investigational...
1y agoRGNXREGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational HighlightsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m. ET to discuss its financial...
1y agoRGNXREGENXBIO to Participate in Upcoming Investor ConferencesPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Chardan's 9th Annual Genetic Medicines...
1y agoRGNXREGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual MeetingPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery...
1y agoRGNXREGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMDPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the ATMOSPHERE® and ASCENT® pivotal studies evaluating surabgene...
1y agoRGNXREGENXBIO Announces Presentation at the World Muscle SocietyPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Congress of the World...
1y agoRGNXREGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
1y agoRGNXREGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS IIPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced new, positive data from the Phase I/II/III CAMPSIITE® trial of clemidsogene lanparvovec (RGX-121) for...
1y agoRGNXREGENXBIO to Participate in Upcoming Investor ConferencesPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference 1x1...
1y agoRGNXREGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS IIPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) extended its review timeline of the Biologics License...
1y agoRGNXREGENXBIO Inc. (RGNX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoRGNXREGENXBIO Reports Second Quarter 2025 Financial Results and Operational HighlightsPR NewswireREGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2025. "Our REGENXBIO...